Human Papillomavirus (HPV)
- Category: Women & HIV
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
HIV positive women respond well to the Gardasil human papillomavirus (HPV) vaccine, offering them protection against cervical cancer, according to a study published in the April 14 electronic edition of Clinical Infectious Diseases. Related recent research found that both Gardasil and Cervarix are effective in people with HIV.
- Category: Human Papillomavirus (HPV)
- Published on Tuesday, 29 April 2014 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week approved Roche Diagnostics' cobas human papillomavirus (HPV DNA test for initial screening for cervical cancer. The test detects high-risk or cancer-causing HPV types including HPV-16 and HPV-18. Women who test positive for high-risk HPV can then undergo further testing for pre-cancerous or malignant cell changes.
- Category: HPV Vaccines
- Published on Wednesday, 30 October 2013 00:00
- Written by Duke University
African-American women with precancerous cervical abnormalities are about half as likely to have cancer-causing human papillomavirus (HPV) types 16 and 18, and more likely to have other types for which the Gardasil and Cervarix vaccines do not provide protection, according to a study presented at the American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research taking pace this week in Maryland.
- Category: Anal & Cervical Cancer
- Published on Tuesday, 11 March 2014 00:00
- Written by Gregory Fowler
The progression of anal dysplasia is highly variable in people with HIV, progressing in some and remaining stable or regressing in others, according to a retrospective analysis of nearly 3000 participants presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston. Progression to invasive anal cancer, however, was uncommon.
- Category: Continuum of Care
- Published on Monday, 21 October 2013 00:00
- Written by Keith Alcorn
Only 20% of people with HIV in Europe have fully suppressed viral load, compared to an estimated 24% in sub-Saharan Africa, despite much higher rates of HIV diagnosis in the European region, Professor Jens Lundgren of the University of Copenhagen told the 14th European AIDS Conference in Brussels on Saturday.